T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments

SIMPLE SUMMARY: Over the past two decades, there has been significant progress in the treatment of multiple myeloma. Starting with the approval of bortezomib and lenalidomide, followed by newer agents in the same classes, monoclonal antibodies, and most recently idecabtagene vicleucel and ciltacabta...

Descripción completa

Detalles Bibliográficos
Autores principales: Simmons, Gary L., Castaneda Puglianini, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455067/
https://www.ncbi.nlm.nih.gov/pubmed/36077787
http://dx.doi.org/10.3390/cancers14174249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455067/
https://www.ncbi.nlm.nih.gov/pubmed/36077787
http://dx.doi.org/10.3390/cancers14174249

Ejemplares similares